TABLE 1.
Baseline characteristics of the liver transplant recipients and the immunocompetent control group
| Variable | Liver transplant recipients | Controls | p value |
|---|---|---|---|
| n = 120 | n = 27 | ||
| Age (years), median (IQR) | 65 (55–71) | 68 (57–75) | 0.198 |
| Female sex, n (%) | 49 (41.2) | 15 (55.6) | 0.174 |
| Body mass index, median (IQR) | 27.7 (24.4–31.2) | 27.2 (24.1–31.2) | 0.907 |
| Comorbidities, n (%) | |||
| Hypertension | 70 (58.3) | 12 (44.4) | 0.189 |
| Diabetes | 43 (35.8) | 5 (18.5) | 0.112 |
| COPD/asthma | 9 (7.5) | 2 (7.4) | 0.897 |
| Days second‐dose antibody testing, median (IQR) | 56 (40–73) | 64 (45–74) | 0.373 |
| Days between vaccine doses, median (IQR) | 85 (59–107) | 96 (62–127) | 0.969 |
| Vaccine, n (%) | |||
| ChAdOx1 (AstraZeneca) | 35 (29.2) | 8 (29.6) | 0.962 |
| BBIBP‐CorV (Sinopharm) | 25 (20.8) | 5 (18.5) | 0.787 |
| rAd26‐rAd5 (Sputnik V) | 37 (30.8) | 6 (22.2) | 0.374 |
| r d26/mRNA‐1273 (Sputnik V/Moderna) | 23 (19.2) | 8 (29.6) | 0.229 |
| Detectable anti‐spike IgG, n (%) | 74 (61.7) | 24 (88.9) | 0.006 |
| Detectable anti‐spike IgG, n (%) | |||
| ChAdOx1(AstraZeneca) | 16 (45.7) | 8 (100) | 0.005 |
| BBIBP‐CorV (Sinopharm) | 12 (48) | 2 (40) | 0.743 |
| rAd26‐rAd5 (Sputnik V) | 25 (67.6) | 6 (100) | 0.100 |
| rAd26/mRNA‐1273 (Sputnik V/Moderna) | 21 (91.3) | 8 (100) | 0.389 |
| Anti‐spike IgG UI/ml, median (IQR) | 153.5 (68.9–706.4) | 523.3 (85.5–1755.9) | 0.009 |
| Anti‐spike IgG UI/ml, median (IQR) | |||
| ChAdOx1 (AstraZeneca) | 133 (68–495) | 86 (71–189) | 0.256 |
| BBIBP‐CorV (Sinopharm) | 80 (36–327) | 23 (15–32) | 0.329 |
| rAd26‐rAd5 (Sputnik V) | 132 (77–706) | 931 (160–1615) | 0.065 |
| rAd26/mRNA‐1273 (Sputnik V/Moderna) | 690 (73–2473) | 2015 (1642–2587) | 0.041 |
| Detectable neutralizing antibody, n (%) | 66 (55) | 22 (81.5) | 0.016 |
| Neutralizing antibody titers, n (%) | |||
| Low titer (1:2) | 6 (9.1) | 0 (0) | |
| Medium titer (1:4–1:16) | 31(47) | 7 (31.8) | |
| High titer (≥1:32) | 29 (43.9) | 15 (68.2) | 0.090 |
Abbreviations: COPD, chronic obstructive pulmonary disease; IgG, immunoglobulin G; IQR, interquartile range.